Who we partner with
Enhance your lab’s Alzheimer’s testing capabilities with Simoa®. Our test offers a highly scalable, non-invasive biomarker solution for detecting Alzheimer’s pathology.
- Expand your testing menu with a blood-based Alzheimer’s biomarker panel
- Collaborate on validation studies to advance biomarker driven diagnostics
Collaborate on breakthrough studies using our Simoa® platform to investigate Alzheimer’s and neurodegenerative disease biomarkers.
- Partner with us on grant funded research to expand scientific understanding of AD pathology
- Develop novel applications with our parent company, Quanterix
Optimize trial recruitment or biomarker validation with our blood-based testing platform.
- Reduce trial costs by supplementing CSF and PET-based testing
- Leverage our expertise in biomarker validation
Accelerate Alzheimer’s drug development with biomarker testing that supports clinical trials and companion diagnostic development.
- Patient stratification for clinical trials targeting amyloid and tau pathology
- Leverage our expertise in biomarker validation
- Diagnostic validation to support precision medicine approaches
